- Bristol Myers braves failed Reblozyl phase 3, plans FDA talks for potential anemia expansion Fierce Pharma
- BMS’ Anemia Drug Reblozyl Flunks Phase III Myelofibrosis Trial BioSpace
- Bristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint deal closes Endpoints News
- Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here’s What Investors Are Thinking Stocktwits
- Luspatercept Plus Concomitant JAK Inhibitor Therapy Misses Primary End Point in Myelofibrosis-Associated Anemia OncLive
Source link
